

Report No.: TR 066-046H Date: June 10, 2024

Receipt Date: 6/4/2024

Analysis Date: 6/5/2024

Page:

Client: Sovereign Health and Performance **Sample Name:** CJC-1295 (5mg) + Ipamorelin (5mg)

Batch#: CJCIPAE124

Report Date: 6/11/2024

6/11/2024 **Matrix:** Powder Purity **Number of samples:** 1


Certificate of Analysis

Purity: 99.7%

Test:

Data File	20240605_CJC_1295andIpamorelin.d	Sample Name	CJC_1295andIpamorelin
Sample Type	Sample	Position	P2-A9
Instrument Name	Instrument 1	User Name	
Acq Method	PuritydefaultMS2.m	Acquired Time	6/5/2024 9:41:25 PM (UTC-07:00)
IRM Calibration Status	Not Applicable	DA Method	20211216_PIS7_165and211_quad_SCAN_POS_Nowar taDSDPRWV_neat.m
Comment			
Sample Group		Info.	
Stream Name	LC 1	Acquisition Time (Local)	6/5/2024 9:41:25 PM (UTC-07:00)
Acquisition SW	6400 Series Triple Quadrupole B.09.00 (B9037.0)		

Chromatograms



Peak List

Time	Area	%Area		
1.824 min.	17.11	0.2%		
5.711 min.*	8014.09	78.4%		
6.911 min.**	2181.9	21.3%		
8.017 min.	11.27	0.1%		
Combined		99.7%		
purity:		99.7%		

Reviewed and Approved By:

Herman Lelie

Note-percent area between two compounds is not quantitative due to variable extinction coefficients

Constitution Labs (CL) maintains liability limited to cost of analysis. Interpretation and use of test results are the responsibility of the client. This report relates only to the samples reported above, and may not be reproduced, except in full, without written approval by CL. This is not intended as an endorsement of any product. CL bears no responsibility for sample collection activities or analytical method limitations. Samples are within quality control

criteria and met method specifications unless otherwise noted.

^{*} determined as Ipamorelin based on retention time

^{**} determined as CJC-1295 based on retention time